DCT and melanoma: The efficacy of TRP2 knockdown was confirmed by immunoblot; all three shRNAs strongly reduced TRP2 protein expression in melanoma cell lines and the knockdown was most prominent for TRP2-shRNA_#2 (Figure 2).